Masahiro Takeuchi

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.

Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, Sunakawa Y, Takeuchi M, Fujii M.

Gastric Cancer. 2023 Aug 07. PMID: 37548812

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).

Kobayashi K, Masuda N, Mizuno T, Miura K, Tokuda Y, Yoshinami T, Kawaguchi H, Ohtani S, Saeki T, Toi M, Takeuchi M, Ito Y.

Breast Cancer Res Treat. 2023 Oct. 201(3):409-415. PMID: 37480384

Double-hit follicular lymphoma diagnosed due to central nervous system symptoms.

Kawajiri-Manako C, Mishina T, Tsujimura H, Maruyama S, Sato A, Sugawara T, Kumagai K, Nakamura R, Itami M, Takeuchi M.

Ann Hematol. 2023 05. 102(5):1281-1282. PMID: 36971807

Prognosis of Patients With Heart Failure Receiving Autologous Myoblast Patches - Comparison of Single-Arm Trial Data to Registry Data.

Miyagawa S, Kainuma S, Imanishi Y, Shimamoto T, Nitta Y, Matsuo C, Sakata Y, Takeuchi M, Sawa Y.

Circ J. 2023 03 24. 87(4):481-486. PMID: 36384895

A Case of Preserved Blood Flow to the Portal Vein Due to the Concurrent Reconstruction of the Superior Mesenteric Vein and the Splenic Vein Using an Artificial Blood Vessel.

Takeuchi M, Onoda M, Iwamura M, Inokuchi T, Kawano K, Katoh T, Furutani A.

Cureus. 2022 Nov. 14(11):e31457. PMID: 36523740

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.

Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa YU, Takeuchi M, Ichikawa W, Fujii M.

Anticancer Res. 2022 May. 42(5):2675-2681. PMID: 35489740

A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.

Kato H, Maezawa Y, Nishijima D, Iwamoto E, Takeda J, Kanamori T, Yamaga M, Mishina T, Takeda Y, Izumi S, Hino Y, Nishi H, Ishiko J, Takeuchi M, Kaneko H, Koshizaka M, Mimura N, Kuzuya M, Sakaida E, Takemoto M, Shiraishi Y, Miyano S, Ogawa S, Iwama A, Sanada M, Yokote K.

Exp Hematol. 2022 05. 109:11-17. PMID: 35240258

Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.

Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M.

Target Oncol. 2021 11. 16(6):753-760. PMID: 34718946

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12).

Nakamura M, Satake H, Sagawa T, Takagane A, Sekikawa T, Oguchi K, Kaji T, Takeuchi M, Ichikawa W, Fujii M.

Oncol Ther. 2021 Dec. 9(2):635-645. PMID: 34626349

Successful Pre-Operative Local Control of Skin Invasion of Breast Cancer Using a Combination of Systemic Chemotherapy and Mohs Paste.

Takeuchi M, Katsuki T, Yoshida K, Onoda M, Iwamura M, Inokuchi T, Furutani A, Katoh T, Kawano K, Hirata K.

J Breast Cancer. 2021 Oct. 24(5):481-490. PMID: 34725974